Last checked at 20 Jul 2022 20:50
TRADING UPDATES: Angle hails study find; Eqtec buys plant in France
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Angle Share News (AGL)
AGL Share
Price
AGL Share
News
AGL Share
Chat7
AGL Share
Trades31
AGL
Live RNS
AGL Share
Charts
AGL Level 2
Console
AGL Live
Share Price
AGL Broker
Ratings
AGL Directors
Deals
AGL Financial
Diary
AGL
Fundamentals
AGL Short
Positions
AGL
Media
Angle Information
Share Price Information for Angle (AGL)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
14.75
Bid:
14.00
Ask:
15.50
Change:
-0.75 (-4.84%)
Spread:
1.50 (10.714%)
Open:
16.00
High:
16.00
Low:
14.75
Prev. Close:
15.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.19 Jul 2022 16:35
Director dealings: Angle CEO, finance chief join capital raise
(Sharecast News) - Liquid biopsy specialist Angle had two entries on the list of director buys on Tuesday, after its chief executive and chief financial officers invested in shares.
Read more15 Jul 2022 17:13
LONDON MARKET CLOSE: Stocks higher as US rate hikes fears calm
(Alliance News) - Stocks in London ended the week in the green after positive retail sales data from the US, easing fears over future US interest rate hikes.
Read more15 Jul 2022 14:45
IN BRIEF: Angle raises GBP20 million to progress Parsortix
Angle PLC - Surrey, England-based medical diagnostics company - Raises GBP20.1 million via share placing, marginally above the GBP20.0 million it aimed for.
Read more15 Jul 2022 11:21
AIM WINNERS & LOSERS: Fevertree lowers guidance; DP Poland sales rise
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
Read more14 Jul 2022 21:44
TRADING UPDATES: Shield closer to Canada approval; Angle plans raise
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more22 Jun 2022 10:27
Angle wins additional contract with large-scale pharma company
(Sharecast News) - Liquid biopsy company Angle has secured an additional contract with its first large-scale pharmaceutical services customer.
Read more22 Jun 2022 10:01
Angle wins cancer monitoring contract for Parasortix system
(Alliance News) - Angle PLC on Wednesday said it has secured further business with its "first large scale pharma services" customer.
Read more16 Jun 2022 16:55
TRADING UPDATES: Valereum opens NFT market; Conygar considers raising
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more14 Jun 2022 20:13
IN BRIEF: Angle's Parsortix performs well on prostate cancer patients
Angle PLC - Surrey, England-based medical diagnostics company - Notes researchers at King's College London published data investigating the role of invasive cellular protrusion, known as invadopodia, activity in prostate cancer, and a potential role in the formation of circulating tumour cells. Researchers used Angle's Parsortix system's ability to isolate CTCs from the blood of prostate cancer patients. Parsortix system isolates CTCs in 94% of prostate cancer patients, showing some association with matrix degradation and invasive cellular protrusion formation. This may allow novel therapeutic development targeting the mechanisms of invadopodia and reducing metastatic spread of the cancer, it says.
Read more30 May 2022 15:21
IN BRIEF: Angle partners with US urology group for Parasortix study
Angle PLC - Surrey, England-based medical diagnostics company - Establishes partnership with MidLantic Urology to evaluate the use of its Parasortix system in prostate cancer clinical studies. MidLantic is as an affiliate of special urology services provider Solaris, which has over 500 clinical urology providers across 179 locations in the US, with over 729,000 annual patients. Angle hopes the collaboration will "enable potential sales" to Solaris' patient base. The first study is expected to start in the third quarter of 2022, with results to be available in 2023.
Read more27 May 2022 21:25
TRADING UPDATES: Savannah Energy to develop new projects in Chad
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
Read more25 May 2022 21:19
IN BRIEF: Angle shares rocket as Parasortix receives US FDA approval
Angle PLC - Surrey, England-based medical diagnostics company - Receives approval from the US Food & Drug Administration for the use of its Parasortix system for use in metastatic breast cancer patients. Parasortix isolates circulating tumour cells from the blood which can aid in the diagnosis, characterisation and monitoring of cancer, and do so in a much less invasive fashion than traditional tissue biospy.
Read more25 May 2022 17:06
LONDON MARKET CLOSE: Stocks rise ahead of US Fed meeting minutes
(Alliance News) - Stocks in London ended mostly higher on Wednesday as market participants look ahead to the latest minutes from the US Federal Reserve at 1900 BST.
Read more20 May 2022 13:07
Angle's Parsortix to be used in 'significant' prostate cancer study
(Sharecast News) - Liquid biopsy company Angle announced on Friday that Prostate Cancer UK has approved funding for a "significant" clinical study at the Barts Cancer Institute of the Queen Mary University of London.
Read more